HiberGene Diagnostics, the leading manufacturer of molecular diagnostics products in Ireland, is pleased to announce that it will supply its innovative point-of-care (POC) and near-patient testing solutions directly to healthcare providers in the UK and Ireland. These high-quality testing solutions cover infectious and transmissible disease areas – including respiratory, sexually transmitted infections, hospital acquired infections, and women’s health – and are designed to revolutionise turnaround times for results in almost any setting, bringing cost and time savings while improving patient management.
To complement the opening of its UK division, HiberGene is proud to be sponsoring UK NEQAS’ multi-disciplinary event Supporting your point of care testing (POCT) service on 30 June 2022. The company will attend this one-day seminar at the Hyatt Regency Hotel, Birmingham, to take part in key discussions on accrediting and implementing these services in a healthcare setting, and the benefits that this can bring for both patients and clinicians.
David Corr, CEO of HiberGene, commented: “After immense success in Ireland, we are excited to announce the launch of our new, dedicated UK team, increasing our geographical reach and capabilities for our growing customer base. Our multi-disciplinary teams possess deep technical knowledge on a wide variety of testing options to deliver the best solution for each customer and look forward to showcasing their knowledge in key discussions at the UK NEQAS event.”
For more information about Hibergene, visit the website.
To find out more about this event, register your attendance online.
